Wall Street Zen Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to "Strong-Buy"

Wall Street Zen upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL - Free Report) from a buy rating to a strong-buy rating in a research report released on Saturday.

Several other equities research analysts also recently commented on the company. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of "Buy" and an average target price of $43.75.

Collegium Pharmaceutical Stock Up 0.8%

COLL traded up $0.23 during trading hours on Friday, hitting $29.83. 669,952 shares of the company's stock were exchanged, compared to its average volume of 405,163. The stock has a market cap of $958.44 million, a price-to-earnings ratio of 24.45 and a beta of 0.63. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $42.29. The stock's 50-day moving average is $28.57 and its two-hundred day moving average is $29.52. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The business had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same period last year, the firm earned $1.45 earnings per share. The company's quarterly revenue was up 22.7% compared to the same quarter last year. Sell-side analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, Director John Gordon Freund sold 6,601 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director now directly owns 70,658 shares of the company's stock, valued at $2,163,547.96. This represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.51% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its holdings in Collegium Pharmaceutical by 19.5% in the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the period. Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after purchasing an additional 5,480 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its stake in shares of Collegium Pharmaceutical by 1.4% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,371,448 shares of the specialty pharmaceutical company's stock worth $40,938,000 after purchasing an additional 19,568 shares during the period. Emerald Advisers LLC lifted its holdings in Collegium Pharmaceutical by 1.8% during the 1st quarter. Emerald Advisers LLC now owns 826,475 shares of the specialty pharmaceutical company's stock worth $24,670,000 after purchasing an additional 14,795 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Collegium Pharmaceutical by 18.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock worth $21,309,000 after purchasing an additional 109,655 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.